Management Team
Hilde H Steineger
CEO employed since 2025, born 1966. 0 shares and 1 000 000 options
Hilde H Steineger har omfattande erfarenhet av ledande befattningar på både chefs- och styrelsenivå inom life science-sektorn, med fokus på finansiell analys, riskkapital, affärsutveckling och ledningsroller. Steineger var tidigare VD för Staten Biotechnology samt COO och medgrundare av NorthSea Therapeutics.
Tidigare befattningar inkluderar Head of Strategic Innovation Management inom Nutrition and Health Division på BASF, samt Head of Global Omega-3 Innovation Management – som omfattar funktioner inom forskning och utveckling, medicinska frågor och affärsutveckling. Hon har en bred finansiell bakgrund som finansanalytiker på Nordea Securities och riskkapitalist på NeoMed Management samt styrelseerfarenhet i både börsnoterade och privata bioteknikföretag, inklusive Algeta ASA (förvärvat av Bayer AG), OncoInvent och Strongbridge Biopharma plc. Steineger har en doktorsexamen i medicinsk biokemi (Oslos universitet, 2000) och en magisterexamen i molekylärbiologi/bioteknik (1992).
David Liberg
CSO employed since 2015, born 1969. Holdings: 69 087 shares and 630 000 options
David Liberg graduated with a PhD in 2001 and has over twentyfive years of research experience within immunology and tumour biology. Liberg has worked within the pharmaceutical industry for the last eighteen years, with responsibility for early research projects and activities in tumour immunology. He has extensive experience of pre-clinical phase cancer projects. His most recent position was at Active Biotech AB, where he worked as Project Manager Drug Development as well as Head of Cell Biology and Biochemistry. Liberg has also carried out research at Imperial College in the UK and at Lund University.
Patrik Renblad
CFO employed since 2023, born 1970. Holdings: 141 405 shares and 600 000 options
Patrik Renblad holds a MSc in Business Administration and Economics from Lund University. He has more than 20 years of experience from the Life Science industry. With a strong financial background and focus, he has served in various roles across the pharmaceutical value chain and across geographies for AstraZeneca, LEO Pharma and SynAct Pharma. Prior to joining Cantargia, Renblad led SynAct Pharmas listing on Nasdaq Stockholm in 2022 as CFO. Before that, he served 10 years at LEO Pharma, amongst his roles were head of Research & Development Finance unit and local CFO for the Chinese affiliate in Shanghai.
Ton Berkien
CBO employed since 2024, born 1968. Holdings: 53 423 shares and 450 000 options
Ton Berkien holds a BA degree in economics/business information from Saxion University of Applied Sciences in the Netherlands, as well as an LSid from SIMI and from PwC/Harvard Business School/IMD. He has more than 20 years of experience in the Life Science Industry. Berkien has previously held senior business development positions at Amgen, Nuevolution, Takeda and Nycomed. Before that he held positions at Ferring Pharmaceuticals, PwC, KPMG and Gilde Investment Management. Further, he is Chairman of the Board in Gedea Biotech AB and board member in Adjutec Pharma A/S.
Morten Lind Jensen
CMO since 2025, born 1979. Holdings: 0 shares and 0 options
Morten Lind Jensen is an MD and holds PhD, from University of Copenhagen, Denmark and a Diploma in Pharmaceutical Medicine from the Royal Colleges of Physicians of the United Kingdom. He has more than 10 years of experience from the Life Science industry. Prior to Cantargia, Lind Jensen held the position as Chief Medical Officer at UNION therapeutics A/S, where he worked in clinical development. He has served in various roles at Novo Nordisk such as medical specialist, Project Manager and Line Manager. His experience covers the therapeutic areas of Hidradenitis Suppurativa, Atopic Dermatitis, Psoriasis, Ulcerative Colitis and viral airway infections. Lind Jensen is currently a board member of HEDIA A/S, and BIBAWO Medical A/S.
